Scientists have successfully engineered the most complicated human cell lines ever, indicating that our genomes are more tolerant to significant structural alterations than previously assumed.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was ...

Cathie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...